Development of Non-Narcotic Intravenous Analgesics
Development of Non-Narcotic Intravenous Analgesics
批准号:
7161522
负责人:
KENNETH W NARDUCY
金额:
$11.19万
依托单位国家:
美国
项目类别:
财政年份:
2007
资助国家:
美国
项目状态:
已结题
起止时间:
2007-03-06 至 2008-03-05
关键词:
Absence of pain sensationAcetaminophenAcuteAcute PainAnalgesicsBack PainBiological AvailabilityBlood ClotBlood coagulationCancer PatientCharacteristicsClinical ResearchConditionDevelopmentDiseaseDoseElderlyEmbolismFormalinFundingGlutathioneHepaticHepatitisHepatotoxicityHumanHyperalgesiaInjectableInjuryIntravenousLeadLegal patentLicensingLiverMeasuresMetabolicMigraineNarcoticsOralOral AdministrationPainPatientsPharmaceutical ChemistryPharmaceutical PreparationsPharmacologic SubstancePhasePlasmaPopulationPostoperative PainPreclinical TestingPrincipal InvestigatorProdrugsSCP 1SafetySeriesSmall Business Funding MechanismsSmall Business Innovation Research GrantSodiumSodium ChlorideSolubilityStructureTechnologyTherapeuticTimeTitrationsToxic effectTransaminasesUnconscious StateUnited States Food and Drug AdministrationWaterabsorptionanalogbasedesireefficacy trialimprovedliver functionmouse modelnovelproblem drinkerprogramspropacetamolresponsesuccesswater solubility
中文摘要
点击翻译按钮获取中文摘要
英文摘要
DESCRIPTION (provided by applicant): Intravenous drug administration is often clinically desired over oral administration, particularly for patients who have difficulty taking an oral drug due to their disease or condition (eg, unconsciousness, anesthetized). IV administration also produces a faster therapeutic onset and permits more accurate dose administration and titration. Although variables related to drug absorption are circumvented by IV administration, IV drugs must have good water solubility to avoid issues related to blood clotting and formation of embolisms. Therefore, the solubility characteristics of new drug candidates have a significant effect on their chance for therapeutic (and commercial) success. We have been exploring a series of new and proprietary analogs of acetaminophen that show good oral efficacy but are devoid of hepatotoxic effects. Under this Phase I project we will prepare water-soluble analogs of these compounds, and determine the feasibility for further development of each of these target-candidate compounds as IV analgesics. This technology will fulfill one of our target profiles, defined as a drug that is clinically useful as an IV treatment for postoperative pain and other types of pain, including patients that may have compromised liver function (eg. elderly, cancer patients, and patients with alcoholic liver injury or hepatitis).
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Novel drug combinations for the management of pain
-
批准号:7054738
-
项目类别:
-
资助金额:$53.57万
-
财政年份:2003
-
负责人:KENNETH W NARDUCY
-
依托单位:
Development of SCP-1/opioid combinations for pain
-
批准号:6582854
-
项目类别:
-
资助金额:$9.99万
-
财政年份:2003
-
负责人:KENNETH W NARDUCY
-
依托单位:
ANALGESICS FOR CHRONIC PAIN TREATMENT IN THE ELDERLY
-
批准号:6298399
-
项目类别:
-
资助金额:$10.0万
-
财政年份:2001
-
负责人:KENNETH W NARDUCY
-
依托单位:
DEVELOPMENT OF ANALGESICS WITH FEWER SIDE EFFECTS
-
批准号:6142110
-
项目类别:
-
资助金额:$10.0万
-
财政年份:2000
-
负责人:KENNETH W NARDUCY
-
依托单位:
Development of SCP-1 to Treat Pain in the Elderly
-
批准号:6644083
-
项目类别:
-
资助金额:$22.81万
-
财政年份:2000
-
负责人:KENNETH W NARDUCY
-
依托单位:
Development of SCP-1 to Treat Pain in the Elderly
-
批准号:6806430
-
项目类别:
-
资助金额:$27.1万
-
财政年份:2000
-
负责人:KENNETH W NARDUCY
-
依托单位:
Development of Novel Therapeutics for Postsurgical Pain
-
批准号:6622254
-
项目类别:
-
资助金额:$39.98万
-
财政年份:1998
-
负责人:KENNETH W NARDUCY
-
依托单位:
Development of Novel Therapeutics for Postsurgical Pain
-
批准号:6444220
-
项目类别:
-
资助金额:$43.53万
-
财政年份:1998
-
负责人:KENNETH W NARDUCY
-
依托单位:
PREVENTING RETINAL NEOVASCULARIZATION WITH NRTS
-
批准号:2165317
-
项目类别:
-
资助金额:$9.99万
-
财政年份:1996
-
负责人:KENNETH W NARDUCY
-
依托单位:
CONTROLLING UVEITIS WITH NRTS
-
批准号:2165303
-
项目类别:
-
资助金额:$9.96万
-
财政年份:1996
-
负责人:KENNETH W NARDUCY
-
依托单位:
国内基金
海外基金
SirT1在Acetaminophen诱发的药物性肝损伤中的作用及机制
-
批准号:81100281
-
项目类别:青年科学基金项目
-
资助金额:24.0万元
-
批准年份:2011
-
负责人:黄卫锋
-
依托单位: